Loading data for ONCY — first visit, this takes a few seconds.

Oncolytics Biotech Inc. (ONCY)

NasdaqCM: ONCY · Real-Time Price · USD

0.84

-0.02 (-2.33%)

At close: Sep 09, 2026, 3:59 PM

0.82

+3.02%

After-hours: 7:45 PM

Alert

The price, the headline numbers and the latest news, in one place.

-1.55% (1D)

Bid	0.59
Market Cap	101M
Revenue (ttm)	n/a
Net Income (ttm)	-37.5M
	1.15
	-0.35
	n/a
	-3.26
P/B (ttm)	-16.22
P/S (ttm)	0.00
Earnings Date	Nov 16, 2026

Ask	1.11
Volume	463,706
Avg. Volume (20D)	1,118,009
Open	0.84
Previous Close	0.86
Day's Range	0.83 - 0.85
52-Week Range	0.73 - 1.51
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ONCY

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitor...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 5, 2001

Employees 29

Stock Exchange NasdaqCM

Ticker Symbol ONCY

Website https://oncolyticsbiotech.com

Full Company Profile

Financial Performance

In 2025, Oncolytics Biotech's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -28.76M, an increase of 26.17%.

Financial Statements

Earnings Surprise

Oncolytics Biotech has released their quarterly earnings on Aug 12, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.11 misses estimates by -0.03, with -37.50% YoY decline.

Next Earnings Release

Oncolytics Biotech Inc. is scheduled to release its earnings on Nov 16, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 week ago · Simply Wall St.

3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts

Looking for biotech stocks with upside that could help people fight illness? Here are three that analysts think might be worth a look.

3 weeks ago · Simply Wall St.

Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials

Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.

1 month ago · InvestorsHub

Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)

Stock Gains on Regulatory DevelopmentOncolytics Biotech Inc. (NASDAQ:ONCY) shares rose 5.

2 months ago · MT Newswires

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree

2 months ago · Stocktwits

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics

The U.S. Patent and Trademark Office granted a new patent covering key aspects of its proprietary manufacturing process for its investigational cancer immunotherapy Pelareorep.

Page 1 of 2

Oncolytics Biotech Inc. (ONCY)